Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 623-624

  Piszczek, Jolanta ^a   Hutchinson, James ^a,b   Partlow, Eric ^a  

^a Island Health   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Enterococcus; Lipopeptide; Synergy; Treatment failure

Indexed keywords

AMPICILLIN; CEFTAROLINE; CEFTRIAXONE; DAPTOMYCIN; VANCOMYCIN;

AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CASE REPORT; CELL WALL; DEATH; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENTEROCOCCAL ENDOCARDITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; INCIDENCE; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN ALLERGY; RELAPSE; STAPHYLOCOCCUS AUREUS; SURFACE CHARGE; VERY ELDERLY; DRUG EFFECTS; ENDOCARDITIS, BACTERIAL; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CEFTRIAXONE; DAPTOMYCIN; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECALIS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84922424241     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku381     Document Type: Letter

References (11)

1. Snyder AH,Werth BJ, Barber KE et al. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. J Antimicrob Chemother 2014; 69: 2148-54.
2. Murdoch DR, Corey GR, Hoen B et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169: 463-73.
3. Munita JM, Cesar AA, Murray BE. Enterococcal endocarditis: can we win the war? Curr Infect Dis Rep 2012; 14: 339-49.
4. Dohmen PM, Guleri A, Capone A et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother 2013; 68: 936-42.
5. Cantón R, Ruiz-Garbajosa P, Chaves R et al. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65: 1126-36.
6. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-52.
7. Balli EP, Venetis CA, Miyakis S. Linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58: 734-8.
8. Sakoulas G, Nonejuie P, Nizet Vet al. Treatment of high-level gentamicinresistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother 2013; 57: 4042-5.
9. Cha R, Grucz RG Jr, Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003; 47: 1598-603.
10. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-2.
11. Snydman DR, McDermott LA, Jacobus NB. Evaluation of in vitro interaction of daptomycin with gentamicin or β-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves. J Chemother 2005; 17: 614-21.